Holen Sie sich die Stockscreener-App
2.22
2.83%
0.10
Schlusskurs vom Vortag:
$2.12
Offen:
$2.09
24-Stunden-Volumen:
17,035
Relative Volume:
0.21
Marktkapitalisierung:
$164.06M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-4.67M
KGV:
-34.96
EPS:
-0.0635
Netto-Cashflow:
-
1W Leistung:
-3.11%
1M Leistung:
+7.39%
6M Leistung:
-7.23%
1J Leistung:
-95.97%
1-Tages-Spanne:
$2.09
$2.215
1-Wochen-Bereich:
$2.09
$2.44
52-Wochen-Spanne:
$1.43
$67.00
Jyong Biotech Ltd Stock (MENS) Company Profile
Firmenname
Jyong Biotech Ltd
Sektor
Branche
Telefon
-
Adresse
-
Compare MENS vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
2.21 | 157.38M | 0 | -4.67M | 0 | -0.0635 |
VRTX
Vertex Pharmaceuticals Inc
|
521.74 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.21 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.49 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.88 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jyong Biotech Ltd Aktie (MENS) Neueste Nachrichten
Jyong Biotech Ltd. Ordinary Shares (NASDAQ: MENS) Share Price, MENS Stock News, MENS Share Price & Updates - Kalkine
A plant-based drug developer will join a two-language online investor event Sept. 6 - Stock Titan
Jyong (MENS) Move: Gains 2.88% to Reach $2.14 on the Day; Current Setup: the Session Ends Within the Reported Technical Boundaries on the DayVolume Nodes - vinanet.vn
Jyong Biotech (MENS) Holds Flat at $2.1 as Shares Consolidate Between Key Support and Resistance LevelsLow Beta Factor - vinanet.vn
Jyong Biotech (MENS) Edges Up to $2.03, Holding a Tight Range Between Support and ResistanceDynamic Hedging - dars.gov.et
Jyong Biotech (MENS) Dips 0.98% to $2.03 as Biotech Stock Tests Range-Bound SupportSafe Entry Stocks - dars.gov.et
Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships - Macau Business
Jyong Biotech Ltd (MENS) Institutional Confidence - TradingKey
Jyong Biotech Ltd (MENS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Jyong Biotech Ltd (MENS) Income Statement - TradingKey
Jyong Biotech Ltd (MENS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MENS|Jyong Biotech Ltd|Price:2.360|Chg%:-0.350 - TradingKey
Jyong Biotech Ltd (MENS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jyong Biotech Ltd (MENS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Jyong Biotech Ltd (MENS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jyong Biotech Ltd (MENS) Balance Sheet - TradingKey
Jyong Biotech Ltd (MENS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Jyong Biotech pursues global licensing partnerships for BPH drug By Investing.com - Investing.com Nigeria
Jyong Biotech targets $22B global BPH market wi... - Pluang
Jyong Biotech pursues global licensing partnerships for BPH drug - Investing.com
Jyong Biotech Ltd. Reaffirms Global Licensing Strategy for Botanical BPH Drug Candidate Botreso - Quiver Quantitative
Benign prostatic hyperplasia patients projected to reach 150M-156M by 2035 - Stock Titan
Jyong Biotech (MENS) Gains 3.88% as Positive Momentum Targets Key ResistanceFactor Momentum - Vinanet
Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Down 36.2% in June - MarketBeat
Jyong Biotech (MENS) Dips 1.3% as Stock Approaches Key Support at $2.16Value Area Low - vinanet.vn
Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention - Macau Business
Jyong Biotech presents drug candidate at BIO 2026 convention By Investing.com - Investing.com Nigeria
Jyong Biotech presents drug candidate at BIO 2026 convention - Investing.com
Jyong Biotech advances botanical drug Botreso® at BIO 2026, targeting global licensing for BPH treatment. - Pluang
Jyong Biotech (MENS) Retreats Over 5% as Key Support Test LoomsForce Index - dars.gov.et
Price to sales forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Enterprise value to EBIT forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Enterprise value to EBITDA forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Price to book forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Jyong Biotech Ltd. (MENS) Modest Gain Amidst Tight Trading RangeDefined Outcome ETF - DonanımHaber
Jyong Biotech Ltd (MENS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Number of shareholders of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Jyong Biotech Ltd (MENS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Certain Ordinary Shares of Jyong Biotech Ltd. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
JYONG BIOTECH LTD (MENS) Stock Chart - ChartMill
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview - digitalmore.co
Jyong Biotech outlines FDA approval path for botanical drug Botreso® targeting benign prostatic hyperplasia. - Pluang
Jyong Biotech (MENS) Remains Range-Bound as Price Consolidates Near SupportPut Flow Alert - The Legal Advocate
MENS - Finviz
Jyong Biotech Ltd. (MENS) Rises 2.36% as Stock Approaches Key ResistanceElliott Wave Count - dars.gov.et
Jyong Biotech Ltd. (MENS) Surges 3.37% as Buyers Defend Key Support LevelTake Profit Levels - The Legal Advocate
Jyong Biotech Ltd. (MENS) Shows Resilience: Uptick from Key Support ZoneImbalance Zone - The Legal Advocate
Jyong Biotech Ltd. (MENS) Gains 3.37% as Technical Support Holds, Resistance in FocusIV Rank - Newser
Jyong Biotech Ltd. (MENS) Stabilizes Near Key Support After Modest UptickIchimoku TK Cross - Newser
Finanzdaten der Jyong Biotech Ltd-Aktie (MENS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):